Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 137800
Corporate User License Price USD 6000
Corporate User License Price INR 413400
Site License Price USD 4000
Site License Price INR 275600
Request a Quote

Report Title

Meningitis-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Meningitis-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Meningitis-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Meningitis-Pipeline Review, H1 2017



Executive Summary

Meningitis-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Meningitis-Pipeline Review, H1 2017, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.

Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening.Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one of these, and causes meningococcal meningitis. Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B. This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximatiely 44-46% cases of bacterial meningitis have all of the following three symptoms-severe headache, nuchal ridgidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If nove of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely.Other clinical feature include photophobia (fear of bright light), phonophobia (fear of loud noises). In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby head) may be visible. Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Meningitis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 3 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Meningitis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Meningitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Meningitis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Meningitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Meningitis (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Meningitis-Overview

Meningitis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Meningitis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Meningitis-Companies Involved in Therapeutics Development

Chongqing Zhifei Biological Products Co Ltd

ContraFect Corp

Matinas BioPharma Holdings Inc

Viamet Pharmaceuticals Inc

Meningitis-Drug Profiles

(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-302-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-303-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-305-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-309-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EUC-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningitis vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W135, X, Y] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal [serotype 4, 6A] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Neuraminidase A for Infectious Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target PknD for Tuberculous Meningitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1129-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VY-OZ-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Meningitis-Dormant Projects

Meningitis-Discontinued Products

Meningitis-Product Development Milestones

Featured News & Press Releases

Jun 02, 2017: Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis

May 30, 2017: Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology ASM Microbe 2017 Conference

Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated

Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis

Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis

Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine

Apr 24, 2015: Viamet to Provide Update on VT-1129, Novel Antifungal Program at ECCMID 2015

Sep 11, 2014: Viamet Receives Orphan Drug Designation for VT-1129

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Meningitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Meningitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Meningitis-Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2017

Meningitis-Pipeline by ContraFect Corp, H1 2017

Meningitis-Pipeline by Matinas BioPharma Holdings Inc, H1 2017

Meningitis-Pipeline by Viamet Pharmaceuticals Inc, H1 2017

Meningitis-Dormant Projects, H1 2017

Meningitis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Chongqing Zhifei Biological Products Co Ltd

ContraFect Corp

Matinas BioPharma Holdings Inc

Viamet Pharmaceuticals Inc

Meningitis Therapeutic Products under Development, Key Players in Meningitis Therapeutics, Meningitis Pipeline Overview, Meningitis Pipeline, Meningitis Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person